You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 14, 2025

Details for New Drug Application (NDA): 022161

✉ Email this page to a colleague

NDA 022161 describes LEXISCAN, which is a drug marketed by Astellas and is included in one NDA. It is available from two suppliers. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the LEXISCAN profile page.

The generic ingredient in LEXISCAN is regadenoson. There are nine drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the regadenoson profile page.

Summary for 022161

Tradename:	LEXISCAN
Applicant:	Astellas
Ingredient:	regadenoson
Patents:	2

Pharmacology for NDA: 022161

Mechanism of Action	Adenosine Receptor Agonists

Suppliers and Packaging for NDA: 022161

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
LEXISCAN	regadenoson	SOLUTION;INTRAVENOUS	022161	NDA	Astellas Pharma US, Inc.	0469-6501	0469-6501-89	5 mL in 1 SYRINGE, PLASTIC (0469-6501-89)
LEXISCAN	regadenoson	SOLUTION;INTRAVENOUS	022161	NDA	HF Acquisition Co LLC, DBA HealthFirst	51662-1448	51662-1448-1	1 SYRINGE, PLASTIC in 1 CARTON (51662-1448-1) / 5 mL in 1 SYRINGE, PLASTIC

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION;INTRAVENOUS			Strength	0.4MG/5ML (0.08MG/ML)
Approval Date:	Apr 10, 2008	TE:	AP	RLD:	Yes
Patent:	8,106,183	Patent Expiration:	Feb 2, 2027	Product Flag?		Substance Flag?	Y	Delist Request?
Patent:	RE47301	Patent Expiration:	Feb 2, 2027	Product Flag?	Y	Substance Flag?		Delist Request?

Expired US Patents for NDA 022161

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astellas	LEXISCAN	regadenoson	SOLUTION;INTRAVENOUS	022161-001	Apr 10, 2008	7,655,637	⤷ Get Started Free
Astellas	LEXISCAN	regadenoson	SOLUTION;INTRAVENOUS	022161-001	Apr 10, 2008	9,289,446	⤷ Get Started Free
Astellas	LEXISCAN	regadenoson	SOLUTION;INTRAVENOUS	022161-001	Apr 10, 2008	8,470,801	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.